HC Wainwright reissued their buy rating on shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in a report released on Friday morning. They currently have a $6.00 price objective on the biopharmaceutical company’s stock.

CPRX has been the topic of several other reports. Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 7th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $5.00 target price on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 1st. Finally, Zacks Investment Research raised Catalyst Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, October 31st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $5.50.

Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.12 during trading on Friday, hitting $2.87. The stock had a trading volume of 2,011,700 shares, compared to its average volume of 872,389. Catalyst Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $3.24.

WARNING: “Catalyst Pharmaceuticals, Inc. (CPRX) Earns Buy Rating from HC Wainwright” was published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/13/catalyst-pharmaceuticals-inc-cprx-earns-buy-rating-from-hc-wainwright.html.

In other news, insider Patrick J. Mcenany bought 20,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The shares were purchased at an average cost of $2.58 per share, with a total value of $51,600.00. Following the completion of the acquisition, the insider now owns 4,471,026 shares of the company’s stock, valued at approximately $11,535,247.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 8.79% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Nationwide Fund Advisors bought a new stake in Catalyst Pharmaceuticals during the second quarter worth approximately $111,000. New York State Common Retirement Fund bought a new stake in Catalyst Pharmaceuticals during the second quarter worth approximately $114,000. Bank of New York Mellon Corp increased its stake in Catalyst Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock worth $135,000 after acquiring an additional 2,404 shares during the last quarter. SG Americas Securities LLC bought a new stake in Catalyst Pharmaceuticals during the third quarter worth approximately $144,000. Finally, State of Wisconsin Investment Board bought a new stake in Catalyst Pharmaceuticals during the second quarter worth approximately $149,000. 40.19% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.